Source file signed link, expires in 15 minutes
Extracted text 10
Page 1
Page 2
Page 3
LAPORAN HASIL PELAKSANAAN THE REPORT OF RESULTS OF
PAPARAN PUBLIK TAHUNAN (“PUBLIC EXPOSE”) THE ANNUAL PUBLIC EXPOSE (“PUBLIC EXPOSE”) OF
PT SARANA MEDITAMA METROPOLITAN Tbk PT SARANA MEDITAMA METROPOLITAN Tbk
(“SAME”) (“SAME”)
Lampiran I Appendix I
RINCIAN PENYELENGGARAAN PUBLIC EXPOSE DETAILS OF PUBLIC EXPOSE IMPLEMENTATION
SAME telah menyelenggarakan Public Expose pada SAME has conducted a Public Expose which was held at
waktu dan tempat sebagai berikut: place and time as follows:
Hari/ Day : Rabu / Wednesday
Tanggal/ Date : 18 Juni/ June 2025
Waktu/ Time : 15.50 – 16.43 WIB
Tempat/ Venue : Studio SCTV, SCTV Tower Lantai 8
Senayan City, Jl. Asia Afrika Lot. 19,
Jakarta Pusat 10270 – Indonesia.
Pihak manajemen SAME yang hadir pada saat Public The management team of SAME who was present at the
Expose adalah sebagai berikut: Public Expose is as follows:
1. Bapak / Mr. Jusup Halimi selaku Presiden Direktur/ as President Director;
2. Ibu / Ms. dr. Juniwati Gunawan, M.M., selaku Wakil Presiden Direktur/ as Vice President Director;
3. Ibu / Ms. dr. Meta Dewi Thedja, Ph.D, selaku Direktur/ as Director;
4. Ibu / Ms. dr. Kusmiati, MARS, FISQua, selaku Direktur/ as Director;
5. Ibu / Ms. drg. Nailufar, MARS, selaku Direktur/ as Director;
6. Bapak / Mr. Armen Antonius Djan selaku Direktur/ as Director.
Public Expose dibuka oleh seorang pembawa acara The Public Expose began with an introduction by a
yang menjelaskan susunan acara Public Expose yang presenter who then explained the order of events in the
akan diawali dengan pemaparan materi dan diakhiri Public Expose which would begin with a presentation of
dengan sesi tanya-jawab. material and end with a question and answer session.
Dalam pemaparan materi Public Expose, terdapat 4 In presenting the Public Expose material, there were 4
(empat) anggota Direksi yang menjelaskan mengenai 3 (four) members of the Board of Directors who explained
(tiga) agenda, yaitu: 3 (three) agendas, namely:
1. Agenda Pertama mengenai Gambaran Umum 1. The First Agenda regarding the Company Overview
Grup SAME telah disampaikan oleh Bapak Jusup of SAME Group was presented by Mr. Jusup Halimi;
Halimi;
2. Agenda Kedua mengenai Inisiatif Strategis Grup 2. The Second Agenda regarding the Strategic
SAME telah disampaikan oleh Ibu dr. Juniwati Initiatives of SAME Group was presented by Ms. dr.
PT Sarana Meditama Metropolitan Tbk REPORT OF PUBLIC EXPOSE RESULTS: APPENDIX I | 1
Jl. Pulomas Barat VI No. 20, Kayu Putih,
Pulo Gadung, Jakarta Timur 13210, Indonesia
WA: +62881 080 779977 | Contact Center: 150 789
www.emc.id
Page 4
LAPORAN HASIL PELAKSANAAN THE REPORT OF RESULTS OF
PAPARAN PUBLIK TAHUNAN (“PUBLIC EXPOSE”) THE ANNUAL PUBLIC EXPOSE (“PUBLIC EXPOSE”) OF
PT SARANA MEDITAMA METROPOLITAN Tbk PT SARANA MEDITAMA METROPOLITAN Tbk
(“SAME”) (“SAME”)
Gunawan, M.M., dan Ibu dr. Meta Dewi Thedja, Juniwati Gunawan, M.M., and Ms. dr. Meta Dewi
Ph.D.; dan Thedja, Ph.D.; and
3. Agenda Ketiga mengenai Evaluasi Kinerja Grup 3. The Third Agenda regarding SAME Group
SAME telah disampaikan oleh Bapak Armen Performance Review was presented by Mr. Armen
Antonius Djan. Antonius Djan.
Setelah pemaparan materi Public Expose selesai, acara After the Public Expose material was presented, the
dilanjutkan dengan sesi tanya-jawab yang dimoderasi event continued with a question and answer session,
oleh sekretaris perusahaan SAME, Ibu Rahmiyati which was moderated by SAME's corporate secretary,
Yahya. Ms. Rahmiyati Yahya.
Dalam sesi tanya-jawab tersebut, terdapat 3 (tiga) During the question and answer session, there were 3
wartawan yang mengajukan pertanyaan, yang (three) journalists who asked questions which were all
seluruhnya telah dijawab oleh Direksi SAME. answered by SAME’s Board of Directors.
Public Expose ini selesai dan ditutup pada pukul 16.43 The Public Expose was finished and closed at 16.43
WIB. Western Indonesia Time.
PT Sarana Meditama Metropolitan Tbk REPORT OF PUBLIC EXPOSE RESULTS: APPENDIX I | 2
Jl. Pulomas Barat VI No. 20, Kayu Putih,
Pulo Gadung, Jakarta Timur 13210, Indonesia
WA: +62881 080 779977 | Contact Center: 150 789
www.emc.id
Page 5
LAPORAN HASIL PELAKSANAAN THE REPORT OF RESULTS OF
PAPARAN PUBLIK TAHUNAN (“PUBLIC EXPOSE”) THE ANNUAL PUBLIC EXPOSE (“PUBLIC EXPOSE”) OF
PT SARANA MEDITAMA METROPOLITAN Tbk PT SARANA MEDITAMA METROPOLITAN Tbk
(“SAME”) (“SAME”)
Lampiran 2 Appendix II
RINGKASAN SESI TANYA-JAWAB SUMMARY OF THE QUESTION AND ANSWER SESSION
1. Tanya-Jawab Pertama First Question and Answer
Nama Name : Inggit
Institusi Institution : Kontan.co.id
Pertanyaan: Questions:
Apakah tahun ini Perseroan tidak akan membagi Will the Company not distribute dividends this
dividen? Jika benar, alasannya apa? Lalu, mengenai year? If so, what is the reason? Then, regarding
Belanja Modal (CAPEX) tahun ini, bagaimana Capital Expenditure (CAPEX) this year, how is it
pembagiannya dan berapa persentasenya? divided, and what is the percentage?
Jawaban: Answers:
Dalam Rapat Umum Pemegang Saham Tahunan During the SAME Annual General Meeting of
SAME yang diadakan sebelum Public Expose ini, Shareholders (AGMS) held prior to this Public
telah disepakati oleh pemegang saham bahwa Expose, it was agreed that SAME would not
SAME tidak membagi dividen untuk tahun buku distribute dividends for the financial year ending 31
yang berakhir per 31 Desember 2024. Hal ini December 2024. This decision was made because
dikarenakan saldo laba bersih Perseroan per the Company’s net profit as of that date remains
tanggal 31 Desember 2024 masih negatif, yang negative, which, in accordance with the provisions
mana sesuai ketentuan Undang-Undang Perseroan of the Company Law, prevents SAME from
Terbatas, SAME belum bisa membagi dividen. distributing dividends.
Mengenai Belanja Modal (CAPEX) di tahun 2025, For Capital Expenditure (CAPEX) in 2025, the
pengeluaran paling besar digunakan untuk majority of funding will be allocated for the
pembelian alat pendeteksi penyakit sejak dini, purchase of an early disease detection device,
Biograph Vision Quadra PET/CT Scanner –PET/CT specifically the Biograph Vision Quadra PET/CT
Scanner tercanggih dan pertama di Asia. Selain itu, Scanner —the most advanced and first PET/CT
belanja modal ini juga digunakan untuk Scanner in Asia. Additionally, this capital
pengembangan lainnya seperti pembangunan expenditure will support other developments,
gedung baru RS EMC Sentul dan rencana pembelian including the construction of a new building for the
alat medis robotik, serta pembelian dan perawatan RS EMC Sentul, the purchase plan of robotic medical
rutin alat-alat medis yang diperlukan untuk equipment, and the purchase and routine
operasional rumah sakit EMC Healthcare. maintenance of medical equipment essential for the
operation of the EMC Healthcare hospital group.
PT Sarana Meditama Metropolitan Tbk REPORT OF PUBLIC EXPOSE RESULTS: APPENDIX II | 1
Jl. Pulomas Barat VI No. 20, Kayu Putih,
Pulo Gadung, Jakarta Timur 13210, Indonesia
WA: +62881 080 779977 | Contact Center: 150 789
www.emc.id
Page 6
LAPORAN HASIL PELAKSANAAN THE REPORT OF RESULTS OF
PAPARAN PUBLIK TAHUNAN (“PUBLIC EXPOSE”) THE ANNUAL PUBLIC EXPOSE (“PUBLIC EXPOSE”) OF
PT SARANA MEDITAMA METROPOLITAN Tbk PT SARANA MEDITAMA METROPOLITAN Tbk
(“SAME”) (“SAME”)
2. Tanya-Jawab Kedua Second Question and Answer
Nama Name : Kemal Prasetia
Institusi Institution : SCTV – Indosiar
Pertanyaan: Questions:
Bagaimana perusahaan melihat prospek How does the company view the future growth
pertumbuhan rumah sakit di masa depan? Apakah prospects of the hospital? What are the current
tantangannya saat ini? challenges?
Jawaban: Answers:
Belakangan ini, terjadi peningkatan populasi Recently, Indonesia has seen an increase in its
penduduk lanjut usia dan menurunnya populasi elderly population alongside a decrease in the
kelompok usia muda di Indonesia, atau yang kita younger population, a phenomenon known as aging
sebut dengan aging population. Perubahan ini population. This shift has significant implications
berdampak terhadap target usaha rumah sakit for hospitals, which are now focusing on
yang kini memberikan pelayanan dengan menjaga maintaining the health of the elderly and providing
kesehatan masyarakat lansia dan melakukan medical procedures for the elderly through
tindakan medis terhadap lansia seperti operasi, surgeries, therapy, endoscopy, and more.
terapi, endoskopi.
Tahun 2025 ini tidak seperti tahun-tahun yang lalu Looking ahead to 2025, we anticipate a different
dimana terdapat wabah penyakit musiman seperti landscape compared to previous years marked by
Demam Berdarah Dengue (DBD), tipes, dan outbreaks of seasonal diseases, including dengue
gangguan pernapasan. Hal ini cukup berdampak fever, typhoid, and respiratory disorders. This
terhadap kinerja usaha rumah sakit Indonesia change will likely impact the performance of
dimana secara keseluruhan, industri kesehatan hospitals in Indonesia, which has already
Indonesia mengalami pertumbuhan single digit. experienced single-digit growth in the healthcare
sector.
Adapun demikian, industri ini merupakan industri Given the dynamic nature of the healthcare
yang dinamis dan akan selalu berkembang dan oleh industry, many new players are beginning to enter
karena itu, banyak pelaku usaha yang baru mulai the market. We remain optimistic that hospital
terlibat dalam industri kesehatan. Kami pun tetap activities will continue to grow in the future.
optimis aktivitas rumah sakit kedepannya tetap
dapat bertumbuh.
PT Sarana Meditama Metropolitan Tbk REPORT OF PUBLIC EXPOSE RESULTS: APPENDIX II | 1
Jl. Pulomas Barat VI No. 20, Kayu Putih,
Pulo Gadung, Jakarta Timur 13210, Indonesia
WA: +62881 080 779977 | Contact Center: 150 789
www.emc.id
Page 7
LAPORAN HASIL PELAKSANAAN THE REPORT OF RESULTS OF
PAPARAN PUBLIK TAHUNAN (“PUBLIC EXPOSE”) THE ANNUAL PUBLIC EXPOSE (“PUBLIC EXPOSE”) OF
PT SARANA MEDITAMA METROPOLITAN Tbk PT SARANA MEDITAMA METROPOLITAN Tbk
(“SAME”) (“SAME”)
3. Tanya-Jawab Ketiga Third Question and Answer
Nama Name : Rama
Institusi Institution : Bisnis.com
Pertanyaan: Questions:
Mengenai alat robotic surgery yang beroperasi di Regarding the robotic surgery device that has been
akhir 2024, boleh dijelaskan itu robot apa dan ada operated since the end of 2024, can you explain
berapa jumlahnya? Yang mungkin menarik, berapa what robot it is and how many are there? What
nilai investasi yang dikeluarkan Perseroan untuk might be interesting is how much investment value
menghadirkan robot ini? Bagaimana Perseroan did the Company spend to present this robot? How
melihat target pendapatan pada 2025 ini dengan does the Company see the revenue target in 2025
adanya alat robotic surgery dan juga PET/CT with the presence of the new robotic surgery device
Scanner yang baru? and PET/CT Scanner?
Jawaban: Answers:
Untuk tahun 2025 ini, kami tidak melihat ada For 2025, we do not anticipate any significant
dampak signifikan karena adanya kurva impact due to the learning curve associated with
pembelajaran, baik dengan keberadaan ROSA, the introduction of two advanced medical
Robotic Surgical Assistant yang sudah diluncurkan technologies: ROSA, the Robotic Surgical Assistant
di RS EMC Alam Sutera, maupun dengan launched at EMC Alam Sutera Hospital, and the
keberadaan Biograph Vision Quadra PET/CT Biograph Vision Quadra PET/CT Scanner
Scanner yang baru dibeli pada bulan Mei 2025. Hal purchased in May 2025. This is primarily because
ini utamanya dikarenakan tenaga medis kami di our medical personnel at EMC Healthcare require
EMC Healthcare memerlukan waktu untuk time to familiarize themselves with the complex
membiasakan diri dengan teknologi yang kompleks technology of both the robotic device and the
dari perangkat robotik dan PET/CT Scanner PET/CT scanner.
tersebut.
Untuk memfasilitasi hal ini, kami telah To facilitate this, we have sent our orthopedic
mengirimkan para dokter spesialis ortopedi kami specialists to Australia for training on how to use
ke Australia untuk mengikuti pelatihan ROSA. Similarly, the Biograph Vision Quadra, which
penggunaan ROSA. Demikian pula dengan is the most advanced and the first PET/CT scanner
Biograph Vision Quadra yang merupakan PET/CT in Asia, operates quite differently from the analog
Scanner tercanggih dan pertama di Asia, fungsi dan PET/CT scanners that are currently common in
cara menggunakannya sangat berbeda jika Indonesia. Therefore, our medical staff will undergo
dibandingkan dengan PET/CT Scanner analog yang training to operate the Biograph Vision Quadra
saat ini sudah umum di Indonesia. Oleh karena itu, PET/CT scanner effectively. Additionally, while we
tenaga medis kami akan menjalani pelatihan untuk have made the purchase, the PET/CT scanner is not
mengoperasikan Biograph Vision Quadra PET/CT yet operational as we are still awaiting the
Scanner secara efektif. Selain itu, meskipun kami necessary permits from BAPETEN and the Ministry
sudah melakukan pembelian, PET/CT Scanner ini of Health. Consequently, due to the learning curve
belum beroperasi karena kami masih menunggu
PT Sarana Meditama Metropolitan Tbk REPORT OF PUBLIC EXPOSE RESULTS: APPENDIX II | 1
Jl. Pulomas Barat VI No. 20, Kayu Putih,
Pulo Gadung, Jakarta Timur 13210, Indonesia
WA: +62881 080 779977 | Contact Center: 150 789
www.emc.id
Page 8
LAPORAN HASIL PELAKSANAAN THE REPORT OF RESULTS OF
PAPARAN PUBLIK TAHUNAN (“PUBLIC EXPOSE”) THE ANNUAL PUBLIC EXPOSE (“PUBLIC EXPOSE”) OF
PT SARANA MEDITAMA METROPOLITAN Tbk PT SARANA MEDITAMA METROPOLITAN Tbk
(“SAME”) (“SAME”)
izin yang diperlukan dari BAPETEN dan associated with these two tools, we expect their
Kementerian Kesehatan. Akibat dari kurva impact in 2025 to remain minimal.
pembelajaran terkait kedua alat ini, kami
perkirakan dampaknya pada tahun 2025 akan
tetap minimal.
Mengenai nilai investasi ROSA, kami tidak dapat We are unable to disclose the investment value of
mengungkapkan karena adanya perjanjian ROSA due to a confidentiality agreement with the
kerahasiaan dengan vendor. Sebaliknya, kami telah vendor. However, we publicly announced the
mengumumkan nilai investasi untuk Biograph investment value of the Biograph Vision Quadra
Vision Quadra PET/CT Scanner kepada publik sejak PET/CT Scanner, which was purchased in May
pembelian dilakukan pada bulan Mei 2025, 2025, as mentioned in the information disclosure
sebagaimana tersebut dalam keterbukaan submitted by our subsidiary, PT Kedoya Adyaraya
informasi yang disampaikan PT Kedoya Adyaraya Tbk (RSGK). Regarding revenue targets, the SAME
Tbk (RSGK), anak usaha kami. Adapun untuk target Group aims to exceed the performance of the first
pendapatan, Grup SAME menargetkan bahwa quarter by the end of 2025.
kinerja di akhir tahun 2025 dapat melebihi kinerja
di kuartal pertama.
PT Sarana Meditama Metropolitan Tbk REPORT OF PUBLIC EXPOSE RESULTS: APPENDIX II | 2
Jl. Pulomas Barat VI No. 20, Kayu Putih,
Pulo Gadung, Jakarta Timur 13210, Indonesia
WA: +62881 080 779977 | Contact Center: 150 789
www.emc.id
Page 9
Page 10
Names mentioned 17 people and organisations named in the text · linked when the evidence is strong
unresolved
person
Jusup
p.3
unresolved
person
dr. Juniwati
p.3
unresolved
person
dr. Meta Dewi Ph.
p.4
unresolved
person
Thedja
p.4
unresolved
person
Armen
p.4
unresolved
person
Rahmiyati
p.4
unresolved
person
Rahmiyati Yahya.
p.4
unresolved
org
Kementerian Kesehatan. Akibat
p.8
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.